Applicable Bluebird In Sample Clauses

Applicable Bluebird In. License Section 1.1 Applicable New In-License Section 1.2 Applicable Pre-Existing In-License Section 1.3 Bankruptcy Code Section 3.7 Biosimilar Application Section 7.2(f) Biosilimar Product Section 1.4 Biosimilar Product Competition Section 4.3(e) Bluebird Preamble Bluebird In-Licensed IP Section 1.5 Bluebird Indemnitees Section 9.6(a) Bluebird Technology Section 1.6 Business Acquisition Section 3.4(b) Business Party Section 3.4(b) Business Program Section 3.4(b) Celgene Preamble Celgene Corp Preamble Celgene Development & Commercialization Program Section 1.7 Celgene Europe Preamble Celgene Indemnitees Section 9.6(b) Celgene Licensed Product In-License Section 1.8 Celgene Licensed Product In-Licensed IP Section 1.9 Celgene Licensed Product IP Section 1.10 Celgene Other In-License Section 1.11 Celgene Regulatory Rights Section 1.12 Celgene Technology Section 1.13 Clinical Study Section 1.14 Combination Product Section 1.30
View SourceView Similar (2)
Applicable Bluebird In. License Section 1.1 Applicable New In-License Section 1.2 Applicable Pre-Existing In-License Section 1.3 Bankruptcy Code Section 3.7 Biosimilar Application Section 7.2(f) Biosilimar Product Section 1.4 Biosimilar Product Competition Section 4.3(e) Bluebird Preamble Bluebird In-Licensed IP Section 1.5 Bluebird Indemnitees Section 9.6(a) Bluebird Technology Section 1.6 Business Acquisition Section 3.4(b) Business Party Section 3.4(b) Business Program Section 3.4(b) Celgene Preamble Celgene Corp Preamble Celgene Development & Commercialization Program Section 1.7 Celgene Europe Preamble Celgene Indemnitees Section 9.6(b) Celgene Licensed Product In-License Section 1.8 Celgene Licensed Product In-Licensed IP Section 1.9 Celgene Licensed Product IP Section 1.10 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
View SourceView Similar (2)
Applicable Bluebird In. License Section 1.1 Applicable New In-License Section 1.2 Applicable Pre-Existing In-License Section 1.3 Bankruptcy Code Section 3.7 Biosimilar Application Section 7.2(f) Biosilimar Product Section 1.4 Biosimilar Product Competition Section 4.3(e) Bluebird Preamble Bluebird In-Licensed IP Section 1.5 Bluebird Indemnitees Section 9.6(a) Bluebird Technology Section 1.6 Business Acquisition Section 3.4(b) Business Party Section 3.4(b) Business Program Section 3.4(b) Celgene Preamble CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. Celgene Corp Preamble Celgene Development & Commercialization Program Section 1.7 Celgene Europe Preamble Celgene Indemnitees Section 9.6(b) Celgene Licensed Product In-License Section 1.8 Celgene Licensed Product In-Licensed IP Section 1.9 Celgene Licensed Product IP Section 1.10 Celgene Other In-License Section 1.11 Celgene Regulatory Rights Section 1.12 Celgene Technology Section 1.13 Clinical Study Section 1.14 Combination Product Section 1.30 Commercialization Section 1.15 Commercially Reasonable Efforts Section 1.16 Competitive Infringement Section 7.1 Control Section 1.17 Covers Section 1.18 Elected Candidate Appendix A EU Section 1.19 EU Regulatory Event Section 1.20 Field Section 1.21 First Commercial Sale Section 1.22 First Indication Section 1.23 Fully Burdened Manufacturing Cost Appendix H GAAP Section 1.24 Gene Editing Section 1.25 In-License Payment Section 1.26 Indemnification Claim Notice Section 9.6(c) Indemnified Party Section 9.6(c) Joint IP Section 5.2 License Agreement Preamble License Agreement Effective Date Preamble License Agreement Term Section 10.1 Licensed IP Section 1.27 Licensed Product Section 1.28 Litigation Conditions Section 9.6(d)(i) Losses Section 9.6(a) Major EU Countries Section 1.20 Manufacturing Section 1.29 Manufacturing and Supply Agreement Section 2.4(c)(ii) CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ...
View Source
Applicable Bluebird In. License Section 1.1 Applicable New In-License Section 1.2 Applicable Pre-Existing In-License Section 1.3 Bankruptcy Code Section 3.7 Biosimilar Application Section 7.2(f) Biosilimar Product Section 1.4
View Source

Related to Applicable Bluebird In

  • Sublicense Fees Licensee will pay Sublicense Fees indicated in Section 3.1(e) of the Patent & Technology License Agreement on or before the Quarterly Payment Deadline for the Contract Quarter.

  • Scope of Collaboration As part of the collaboration, the Controllers will act as Joint Controller. The roles of the Controller and the associated tasks are specified in more detail in Appendix 1. If one party is solely responsible for a data processing operation, this party will implement all relevant data protection provisions on its own responsibility. However, such data processing procedures are not subject to this Agreement. Joint data processing and the type of Personal Data collected and processed within the framework of collaboration are specified in Appendix 1.

  • Grant and Scope of License 1. 1. The Licensor grants you a personal, non-exclusive, non-transferable, non- sublicensable, revocable, world-wide License to reproduce, distribute, communicate to the public, make available, broadcast, electronically transmit or create derivative works using the Licensed Material for the purpose(s) specified in your RightsLink Licence Details only. Licenses are granted for the specific use requested in the order and for no other use, subject to these Terms and Conditions. You acknowledge and agree that the rights granted to you under this License do not include the right to modify, edit, translate, include in collective works, or create derivative works of the Licensed Material in whole or in part unless expressly stated in your RightsLink Licence Details. You may use the Licensed Material only as permitted under this Agreement and will not reproduce, distribute, display, perform, or otherwise use or exploit any Licensed Material in any way, in whole or in part, except as expressly permitted by this License. 1. 2. You may only use the Licensed Content in the manner and to the extent permitted by these Terms and Conditions, by your RightsLink Licence Details and by any applicable laws. 1. 3. A separate license may be required for any additional use of the Licensed Material, e.g. where a license has been purchased for print use only, separate permission must be obtained for electronic re-use. Similarly, a License is only valid in the language selected and does not apply for editions in other languages unless additional translation rights have been granted separately in the License. 1. 4. Any content within the Licensed Material that is owned by third parties is expressly excluded from the License. 1. 5. Rights for additional reuses such as custom editions, computer/mobile applications, film or TV reuses and/or any other derivative rights requests require additional permission and may be subject to an additional fee. Please apply to ▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇@▇▇▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇ or ▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇@▇▇▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇ for these rights.

  • License Maintenance Fees COMPANY shall pay to M.I.T. the following license maintenance fees on the dates set forth below: January 1, 2002 $ [***] January 1, 2003 $ [***] January 1, 2004 $ [***] January 1, 2005 $ [***] Each January 1st thereafter $ [***] This annual license maintenance fee is nonrefundable; however, the license maintenance fee shall be credited to running royalties subsequently due on NET SALES earned during the same calendar year, if any. License maintenance fees paid in excess of running royalties due in such calendar year shall not be creditable to amounts due for future years.

  • License Maintenance Fee LICENSEE will pay to REGENTS an annual license maintenance fee of [Written amount] U.S. Dollars ($Number) on the one (1) year anniversary date of the Effective Date and on each anniversary of the Effective Date thereafter. Notwithstanding the foregoing, the license maintenance fee will not be due and payable on any anniversary of the Effective Date, if on such date the LICENSEE is selling LICENSED PRODUCTS or LICENSED METHODS, and LICENSEE pays an earned royalty to REGENTS.